Skip to main content
Addgene

pIRE4-Bpa
(Plasmid #155342)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 155342 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pEGFP-N1
  • Backbone manufacturer
    Clontech, major modifications
  • Vector type
    Mammalian Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Kanamycin, 50 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    humanized EBpaRS/BstYam
  • Species
    Synthetic; E.coli
  • Promoter PGK/U6

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site unknown (unknown if destroyed)
  • 3′ cloning site unknown (unknown if destroyed)
  • 5′ sequencing primer n/a
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

The plasmid has been developed for efficient incorporation of Bpa in mammalian cells, first reported in Böttke et al, EMBO reports, 2020. With respect to similar plasmids from other labs, this plasmid contains a humanized gene for EBpaRS and 4 copies of the U6-BstYam tRNA cassette downstream of the synthetase cassette.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pIRE4-Bpa was a gift from Irene Coin (Addgene plasmid # 155342 ; http://n2t.net/addgene:155342 ; RRID:Addgene_155342)
  • For your References section:

    Exploring GPCR-arrestin interfaces with genetically encoded crosslinkers. Bottke T, Ernicke S, Serfling R, Ihling C, Burda E, Gurevich VV, Sinz A, Coin I. EMBO Rep. 2020 Sep 14:e50437. doi: 10.15252/embr.202050437. 10.15252/embr.202050437 PubMed 32929862